BCL2L1 and breast cancer: Consistently, using synthetic lethality screen, Marusyk and colleagues identify BCL-2/BCL-xL inhibitors (ABT-737 and ABT-263) as candidates to overcome CAF-induced resistance to lapatinib in breast cancers [37].